Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | NPY1R | P25929 | 2/20 | 0.44 |
| ▸ | NPY2R | P49146 | 2/20 | 0.44 |
| ▸ | NPY4R | P50391 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.44 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30905699 | 0.99 | TFPI (0.53) | TFPIPTH1RKEAP1CXCR4RXFP1 | |
| SCHEMBL30512599 | 0.96 | TFPI (0.56) | TFPIPTH1RKEAP1CXCR4RXFP1 | |
| SCHEMBL30140825 | 0.91 | TFPI (0.52) | TFPIKEAP1RXFP1NPY1RNPY2R | |
| SCHEMBL30262134 | 0.91 | TFPI (0.56) | TFPIPTH1RKEAP1RXFP1NPY1R | |
| SCHEMBL30084577 | 0.90 | TFPI (0.48) | TFPIKEAP1RXFP1NPY1RNPY2R | |
| SCHEMBL30974514 | 0.90 | TFPI (0.54) | TFPIPTH1RRXFP1NPY1RNPY2R | |
| SCHEMBL30905707 | 0.89 | GRIN2D (0.46) | TFPIPTH1RKEAP1 | |
| SCHEMBL31343200 | 0.89 | NPY4R (0.47) | TFPIKEAP1CXCR4NPY1RNPY2R | |
| SCHEMBL30262158 | 0.89 | RXFP1 (0.56) | TFPIPTH1RRXFP1VIPR1ECE1 | |
| SCHEMBL31343254 | 0.89 | TFPI (0.53) | TFPIPTH1RKEAP1RXFP1VIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-26 | — | — | US | disclosed |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | TFPI 946/4885PTH1R 516/4885KEAP1 4762/4885 |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | TFPI 946/4885PTH1R 516/4885KEAP1 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.